Verve Therapeuticsincis A Clinical Stage Genetic Medicine Company Based In Bostonmassachusettsfounded In 2018Verve Is Focused On Developing Gene Editing Therapies To Treat Cardiovascular Diseasesparticularly Atherosclerotic Cardiovascular Diseaseascvd The Company Aims To Change The Traditional Approach To Chronic Care By Offering Single Course Gene Editing Treatments That Target The Underlying Causes Of These Conditions Verve S Pipeline Includes Several Product Candidatessuch As Verve 101 And Verve 102Which Are In Clinical Trials For Familial Hypercholesterolemiaother Candidates Like Verve 201 And Verve 301 Focus On Permanently Modifying Genes Related To Cholesterol Levelsthe Company Collaborates With Various Partnersincluding Beam Therapeuticsnovartisand Eli Lillyto Enhance Its Gene Editing Capabilities And Advance Its Therapiesverve Therapeutics Is Publicly Traded On The Nasdaq Under The Ticker Symbol Verv And Employs Around 274 People
No conferences found for this company.
| Company Name | Verva Pharmaceuticals |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
